Ira A Tabas, MD

Academic Appointments

  • Professor of Pathology & Cell Biology at CUMC
  • Richard J. Stock Professor of Medicine (Immunology)

Current Administrative Positions

  • Vice-Chair of Research, Department of Medicine
Ira A Tabas, MD

Dr. Tabas received his medical degree and his doctorate in biochemistry from Washington University in St. Louis, Missouri. He then completed an internship and residency in internal medicine and a fellowship in endocrinology and metabolism at Columbia University Medical Center in New York City. During that period, Dr. Tabas also conducted a postdoctoral fellowship in the laboratory of Dr. Alan Tall in the Department of Medicine at Columbia University. He joined the Columbia faculty in 1985 and is currently the Richard J. Stock Professor and Vice-Chair of Research in the Department of Medicine and Professor of Pathology and Cell Biology (in Physiology and Cellular Biophysics).

Dr. Tabas' honor include the American Heart Association Established Investigator Award, the Columbia University Doctor Harold and Golden Lamport Research Award, the American Heart Association/ATVB Council Special Recognition Award, the Richard J. Stock Professorship in the Department of Medicine of Columbia University, and the 2011 Alumni Achievement Award from Washington University School of Medicine. He was elected to both the Society for Clinical Investigation and the Association of American Physicians.

Email: iat1@cumc.columbia.edu

Dr. Tabas' research focuses on the molecular-cellular mechanisms of atherosclerosis, with an emphasis on macrophage cell biology, endoplasmic reticulum-induced cell death (apoptosis), mechanisms involved in the generation of clinically dangerous atherosclerotic plaques, translational work in mouse models of atherosclerosis, and mechanistic-based correlative studies on human disease tissue. His recent activities have expanded into mechanisms of atherosclerosis in diabetes and obesity, including new studies on liver and adipose tissue. He has lectured worldwide and published approximately 175 original research articles and reviews. These papers have been published in Cell, Nature, Nature Cell Biology, Nature Reviews Immunology, Cell Metabolism, Journal of Clinical Investigation, Proceedings of the National Academy of Science USA, Journal of Cell Biology, and Journal of Biological Chemistry. He has served on the editorial board of the Journal of Biological Chemistry, was Deputy Editor of the Journal of Clinical Investigation from 2002-2007, and is currently on the Board of Reviewing Editors for Science.

Departments and Divisions

  • Department of Medicine
    Division of Molecular Medicine
    Division of Molecular Medicine
  • Department of Pathology & Cell Biology

Board Certifications

  • Endocrinology
  • Internal Medicine

Areas of Expertise

  • Hospital Medicine
  • Molecular Medicine

Education and Training

  • Washington University School of Medicine, St. Louis, MO
  • Internship: Columbia Presbyterian Medical Center, NY
  • Residency: Columbia Presbyterian Medical Center, NY
  • Fellowship: Columbia Presbyterian Medical Center, NY

Locations

  • CUIMC/Presbyterian Hospital and Vanderbilt Clinic

    622 West 168th Street
    PH 8
    New York, NY 10032
    Phone:
    (212) 305-9430

Centers / Institutes / Programs

  • Institute of Human Nutrition

Provider Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center

Insurance Programs

Please contact the provider's office directly to verify that your particular insurance is accepted.

  • AETNA [Aetna Signature Administrators, EPO, HMO, Medicare Managed Care, NYP Employee Plan, NY Signature, POS, PPO, Student Health]
  • CIGNA [EPO, Great West (National), HMO, POS, PPO]
  • Emblem/GHI [Medicare Managed Care, PPO]
  • Emblem/HIP [ConnectiCare, EPO, Essential Plan, HMO, Medicaid Managed Care, Medicare Managed Care, POS, PPO, Select Care (Exchange), Vytra]
  • Empire Blue Cross/Blue Shield [EPO, HMO, PPO]
  • Local 1199 [Local 1199]
  • MagnaCare (National) [MagnaCare]
  • Medicare [Railroad, Traditional Medicare]
  • Multiplan [Multiplan]
  • Oxford Health Plans [Freedom, Liberty]
  • RiverSpring [Special Needs]
  • UnitedHealthcare [Compass (Exchange), Empire Plan, HMO, Medicare Managed Care, POS, PPO]

This provider does not accept new patients

Lab Locations

  • CUIMC/Presbyterian Hospital and Vanderbilt Clinic

    622 West 168th Street
    PH 8
    New York, NY 10032

Research Interests

  • Cellular and molecular processes related to arterial wall biology and atherogenesis

NIH Grants

  • AMECHANISTIC AND TRANSLATIONAL RESEARCH PROGRAM LINKING IMPAIRED RESOLUTION, DEFECTIVE EFFEROCYTOSIS, AND CLONAL HEMATOPOIESIS TO THE FORMATION OF CLINICALLY DANGEROUS ATHEROSCLEROTIC PLAQUES (Federal Gov)

    Dec 1 2018 - Feb 28 2026

    CLONAL HEMATOPOIESIS AND ATHEROSCLEROSIS (Private)

    Sep 1 2018 - Dec 31 2023

    MECHANISMS OF ATHEROGENESIS IN INSULIN RESISTANCE (Federal Gov)

    Aug 1 2018 - Jun 30 2023

    MACROPHAGE PHACTR1 IN EFFEROCYTOSIS AND ATHEROSCLEROSIS (Private)

    Jan 1 2020 - Dec 31 2021

    TAZ AND YAP IN NON-ALCOHOLIC STEATOHEPATITIS AND ITS COMPLICATIONS (Federal Gov)

    Jan 1 2018 - Dec 31 2021

    CAMKII/MK2 SIGNALING IN CARDIOMETABOLIC DISEASE (Federal Gov)

    Dec 15 2017 - Nov 30 2021

    ENHANCING INFLAMMATION RESOLUTION IN ATHEROSCLEROSIS VIA TARGETED NANOPARTICLE-MEDIATED DELIVERY OF BIOLOGICS (Federal Gov)

    Jan 1 2016 - Dec 31 2020

    SIRNA TARGETING HEPATOCYTE TAZ AS A NOVEL TREATMENT FOR NON-ALCOHOLIC STEATOHEPATITIS (Private)

    Jul 12 2018 - Jul 11 2020

    MERTK CLEAVAGE AND SIGNALING IN ATHEROSCLEROSIS (Federal Gov)

    Mar 15 2016 - Feb 29 2020

    ENHANCING INFLAMMATION RESOLUTION IN ATHEROSCLEROSIS VIA TARGETED NANOPARTICLE-MEDIATED DELIVERY OF BIOLOGICS (Federal Gov)

    Jan 1 2016 - Dec 31 2019

    CLONAL HEMATOPOIESIS AND ATHEROSCLEROSIS (Private)

    Sep 1 2018 - Dec 31 2019

    MECHANISMS OF POLARIZATION OF MONOCYTES BY DAMPS/PAMPS AND C1Q (Federal Gov)

    Jul 1 2018 - Jun 30 2019

    MACROPHAGE-LIPOPROTEIN INTERACTIONS (Federal Gov)

    Jul 15 2017 - Mar 6 2019

    MECHANISMS AND CONSEQUENCES OF STRESS-INDUCED MACROPHAGE DEATH IN ATHEROSCLEROSIS (Federal Gov)

    Mar 1 2013 - Mar 6 2019

    CAMKII IN ADVANCED ATHEROSCLEROSIS AND INSULIN RESISTANCE (Private)

    Jul 1 2017 - Jun 30 2018

    MECHANISMS AND CONSEQUENCES OF STRESS-INDUCED MACROPHAGE DEATH IN ATHEROSCLEROSIS (Federal Gov)

    Mar 1 2013 - Feb 28 2018

    MECHANISMS AND CONSEQUENCES OF STRESS-INDUCED MACROPHAGE DEATH IN ATHEROSCLEROSIS (Federal Gov)

    Mar 1 2013 - Feb 28 2018

    MECHANISMS OF ATHEROGENESIS IN INSULIN RESISTANCE (Federal Gov)

    Feb 1 2013 - Jan 31 2018

    MECHANISMS OF ATHEROGENESIS IN INSULIN RESISTANCE (Federal Gov)

    Feb 1 2013 - Jan 31 2018

    TARGETING HEPATOCYTE TAZ TO TREAT NON-ALCOHOLIC STEATOHEPATITIS (Private)

    Dec 20 2016 - Dec 19 2017

    THE ROLE OF MERTK CLEVAGE IN ADVANCE ATHEROSCLEROSIS (Private)

    Jul 1 2015 - Jun 30 2017

    A NEW HEPATIC DPP4 PATHWAY THAT PROMOTES VISCERAL FAT INFLAMMATION (Private)

    Jul 1 2015 - Jun 30 2017

    TARGETING OF A NOVEL MODULE IN GLUCAGON SIGNALING AS A THERAPEUTIC STRATEGY FOR TYPE 2 (Private)

    Jan 1 2015 - Mar 31 2017

    AUTOPHAGY IN ADVANCED ATHEROSCLEROSIS (Federal Gov)

    Jan 1 2011 - Nov 30 2015

    MECHANISMS OF DEFECTIVE EFFEROCYTOSIS IN ATHEROSCLEREOSIS (Federal Gov)

    Dec 1 2011 - Nov 30 2015

    MECHANISMS OF DEFECTIVE EFFEROCYTOSIS IN ATHEROSCLEREOSIS (Federal Gov)

    Dec 1 2011 - Nov 30 2015

    MECHANISMS OF DEFECTIVE EFFEROCYTOSIS IN ATHEROSCLEREOSIS (Federal Gov)

    Dec 1 2011 - Nov 30 2015

    A NANOTHERAPEUTIC APPROACH TO DEFECTIVE INFLAMMATION RESOLUTION IN ATHEROSCLEROSIS. (Federal Gov)

    Aug 13 2010 - Aug 12 2015

    SPECIALIZED PRO-RESOLVING MEDIATORS IN ATHEROSCLEROSIS (Federal Gov)

    Aug 1 2013 - Jul 31 2015

    SPECIALIZED PRO-RESOLVING MEDIATORS IN ATHEROSCLEROSIS (Federal Gov)

    Aug 1 2013 - Jul 31 2015

    SPECIALIZED PRO-RESOLVING MEDIATORS IN ATHEROSCLEROSIS (Federal Gov)

    Aug 1 2013 - Jul 31 2015

    ROLE OF CAMKLL IN ATHEROSCLEROSIS AND PROATHEROGENIC EFFECTS RELATED TO INSULIN RESISTANCE (Private)

    Jan 1 2011 - Dec 31 2014

    A NOVEL MOLECULAR MECHANISM LINKING PROLONGED ER STRESS WITH THE MITOCHODRIAL PATHWAY OF APOPTOSIS (Private)

    Jul 1 2011 - Jun 30 2013

    CAREER TRACKS TOWARDS EXCELLENCE (Private)

    Jul 1 1993 - Jun 30 2012

    EVALUATING THE EFFECTIVENESS OF M118 IN PREVENTING HUMAN PLA TELET- MEDIATED ARTERIAL THROMBOSIS AND HEMOSTASIS (Private)

    Feb 9 2009 - Feb 9 2012

    ROLE OF INNATE IMMUNITY IN STRESS-INDUCED APOPTOSIS AND PLAQ UE PROGRESSION IN ATHEROSCLEROSIS (Private)

    Jan 1 2010 - Dec 31 2011

    ROLE OF INNATE IMMUNITY IN STRESS-INDUCED APOPTOSIS AND PLAQ UE PROGRESSION IN ATHEROSCLEROSIS (Private)

    Jul 1 2009 - Jun 30 2011

    ROLE OF INNATE IMMUNITY IN STRESS-INDUCED APOPTOSIS AND PLAQ UE PROGRESSION IN ATHEROSCLEROSIS (Private)

    Jul 1 2009 - Jun 30 2011

    NEW GENES AND PATHWAYS INVOLVED IN ATHEROSCLEROSIS PROJECT (Federal Gov)

    Jul 1 1997 - Mar 31 2011

    RESEARCH COLLABORATION AGREEMENT (NMA) W/ GALAXOSMITHKLINE(G SK); UNIVERSITY OF PENNSYLVANIA(PENN) (Private)

    Mar 1 2010 - Feb 28 2011

    INTERACTION OF ATHEROGENIC LIPOPROTEINS WITH MACROPHAGES (Federal Gov)

    Mar 15 1997 - Feb 28 2011